Skip to main content
. 2019 Mar 5;109(3):635–647. doi: 10.1093/ajcn/nqy295

TABLE 6.

Percentage differences (95% CIs) in concentrations of plasma biomarkers of adipokines and inflammatory markers according to total and caffeinated coffee consumption among participants from the Nurses’ Health Study and the Health Professionals Follow-Up Study1

Categories of coffee consumption
Variable Nondrinker ≤1 cup/d 2–3 cups/d ≥4 cups/d Per cup increase P-trend
Total coffee
 Total adiponectin
  n 1195 2406 5790 3404
  Model 1 0 (ref) 1.5 (−1.6, 4.7) 5.8 (2.8, 8.8) 11.5 (8.3, 14.9) 2.2 (1.7, 2.7) <0.001
  Model 2 0 (ref) 0.3 (−2.6, 3.3) 3.0 (0.3, 5.9) 9.3 (6.1, 12.5) 2.0 (1.6, 2.5) <0.001
 HMW adiponectin
  n 359 777 1856 1060
  Model 1 0 (ref) −0.5 (−8.6, 8.4) 12.6 (4.3, 21.7) 24.5 (14.7, 35.0) 5.2 (3.9, 6.5) <0.001
  Model 2 0 (ref) −1.7 (−9.2, 6.4) 7.4 (−0.2, 15.5) 17.2 (8.2, 26.8) 4.1 (2.8, 5.4) <0.001
 Leptin
  n 662 1261 2682 1480
  Model 1 0 (ref) −4.5 (−10.9, 2.4) −6.2 (−11.9, −0.1) −9.2 (−15.2, −2.8) −1.9 (−3.0, −0.7) 0.001
  Model 2 0 (ref) −4.1 (−9.1, 1.1) −3.1 (−7.8, 1.7) −6.4 (−11.3, −1.2) −1.1 (−2.0, −0.2) 0.01
 CRP
  n 1428 2803 6358 3850
  Model 1 0 (ref) −1.9 (−8.5, 5.0) −9.0 (−14.5, −3.1) −12.8 (−18.4, −6.9) −2.9 (−3.9, −1.8) <0.001
  Model 2 0 (ref) −1.9 (−7.8, 4.4) −8.8 (−13.9, −3.5) −16.6 (−21.6, −11.4) −4.1 (−5.1, −3.1) <0.001
 IL-6
  n 869 1709 4116 2404
  Model 1 0 (ref) −3.1 (−7.9, 2.0) −7.0 (−11.2, −2.7) −6.5 (−10.9, −1.9) −0.9 (−1.7, −0.2) 0.02
  Model 2 0 (ref) −2.4 (−7.0, 2.5) −6.3 (−10.4, −2.1) −8.1 (−12.4, −3.7) −1.7 (−2.4, −0.9) <0.001
 sTNFR-2
  n 990 1952 4670 2737
  Model 1 0 (ref) −4.8 (−6.8, −2.9) −7.5 (−9.2, −5.7) −7.4 (−9.2, −5.6) −1.1 (−1.4, −0.8) <0.001
  Model 2 0 (ref) −3.6 (−5.5, −1.7) −5.4 (−7.1, −3.7) −5.8 (−7.7, −4.0) −1.0 (−1.3, −0.7) <0.001
Caffeinated coffee
 Total adiponectin
  n 2822 3640 4507 1826
  Model 1 0 (ref) 1.0 (−1.2, 3.2) 4.6 (2.4, 6.8) 9.0 (6.2, 12.0) 1.9 (1.4, 2.5) <0.001
  Model 2 0 (ref) 0.2 (−1.9, 2.3) 3.0 (1.0, 5.2) 8.8 (6.0, 11.7) 1.9 (1.3, 2.4) <0.001
 HMW adiponectin
  n 891 1138 1447 576
  Model 1 0 (ref) −3.4 (−9.0, 2.5) 7.6 (1.6, 13.9) 18.0 (9.8, 26.7) 4.4 (2.9, 5.9) <0.001
  Model 2 0 (ref) −4.1 (−9.3, 1.3) 3.4 (−2.0, 9.2) 13.7 (6.0, 22.0) 3.4 (1.9, 4.9) <0.001
 Leptin
  n 1397 1809 2110 769
  Model 1 0 (ref) −1.9 (−6.9, 3.3) −5.4 (−10.1, −0.6) −7.4 (−13.2, −1.1) −2.0 (−3.2, −0.7) 0.003
  Model 2 0 (ref) −3.1 (−6.8, 0.8) −4.9 (−8.5, −1.1) −5.9 (−10.6, −1.0) −1.4 (−2.4, −0.4) 0.01
 CRP
  n 3232 4120 5005 2082
  Model 1 0 (ref) −2.9 (−7.6, 2.1) −9.0 (−13.2, −4.5) −8.4 (−13.7, −2.7) −2.1 (−3.2, −0.9) <0.001
  Model 2 0 (ref) −3.4 (−7.7, 1.0) −10.7 (−14.6, −6.7) −15.9 (−20.5, −11.1) −3.8 (−4.8, −2.7) <0.001
 IL-6
  n 2037 2539 3220 1302
  Model 1 0 (ref) −1.6 (−5.1, 2.0) −3.7 (−7.0, −0.3) 0.9 (−3.4, 5.4) −0.2 (−1.0, 0.7) 0.70
  Model 2 0 (ref) −1.7 (−5.0, 1.8) −4.1 (−7.3, −0.9) −4.3 (−8.3, −0.04) −1.3 (−2.2, −0.4) 0.003
 sTNFR-2
  n 2333 2916 3631 1469
  Model 1 0 (ref) −2.3 (−3.7, −0.8) −5.0 (−6.3, −3.6) −4.1 (−5.7, −2.3) −1.1 (−1.4, −0.7) <0.001
  Model 2 0 (ref) −1.6 (−3.0, −0.2) −3.6 (−4.9, −2.3) −3.8 (−5.5, −2.1) −1.0 (−1.4, −0.6) <0.001
1

Model 1 was adjusted for sex and age at blood draw (linear and quadratic terms). Model 2 was additionally adjusted for race (white, nonwhite), fasting status (yes or no), cumulative average levels of BMI (in kg/m2; <23.0, 23.0–24.9, 25.0–27.4, 27.5–29.9, or ≥30.0), physical activity (<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, or ≥27.0 metabolic equivalent of task-h/wk), alcohol consumption (0, 0.1–4.9, 5.0–9.9, 10.0–14.9, or ≥15.0 g/d), smoking (never; past: <30; past: ≥30; current: <30; or current: ≥30 pack-years), Alternative Healthy Eating Index dietary score (quintiles), total energy intake (quintiles), caffeine intake (quintiles) calculated from dietary items except coffee (tea, cola beverage, and chocolate), regular multivitamin use (yes or no), regular aspirin or nonsteroidal anti-inflammatory drug use (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), and for women, menopausal status (premenopausal, postmenopausal, or unknown) and menopausal hormone therapy (never, past, or current use). For the analysis of caffeinated and decaffeinated coffee, mutual adjustment was performed. CRP, C-reactive protein; HMW, high-molecular-weight; ref, reference; sTNFR-2, soluble TNF receptor 2.